⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 7 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness

Sonia Cismas Sylvya Pasca Caitrin Crudden Iara Trocoli Drakensjo Naida Suleymanova Simin Zhang Benjamin Gebhard Dawei Song Shiyong Neo Takashi Shibano Terry J. Smith George A. Călin Ada Girnita Leonard Girnita

View at Publisher

Ask AI

Bookmark

Share

Abstract

Effect of combination treatment on p53-activation in skin melanoma malignant phenotype in in vitro 3D models

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cismas et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db643587522472 https://doi.org/10.1158/1541-7786.27035605

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 7 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024
2Supplementary Figure 1 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024
3Supplementary Figure 1 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024
4Supplementary Figure 5 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024
5Supplementary Figure 5 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024

Supplementary Figure 4 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024
Supplementary Figure 4 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024
Supplementary Figure 8 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness2024